Stay updated on Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page footer now displays Revision: v3.3.3, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 have been removed.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedA new revision entry v3.3.2 was added and an older revision v3.2.0 was removed from the Record History.SummaryDifference0.1%

- Check50 days agoChange DetectedRemoved the government funding notice banner indicating that information on the site may not be up to date due to funding lapses. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check65 days agoChange DetectedThe Study Record Versions section on the Record History page has a revised layout with checkboxes and headings rearranged, while the list of versions and dates remains unchanged.SummaryDifference0.1%

- Check93 days agoChange Detected- Added a government funding operating-status notice and updated operating details for NIH Clinical Center (high importance). - Updated version from v3.1.0 to v3.2.0 (moderate importance).SummaryDifference13%

- Check100 days agoChange DetectedUpdate revision from v3.0.2 to v3.1.0.SummaryDifference0.3%

Stay in the know with updates to Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.